NovaBridge will present new data on ragistomig at ESMO-IO with Abstract #688 by co-developer ABL Bio on Dec 10th at 5:30 PM.

Unusual Whales
2025.12.04 00:32
NovaBridge Biosciences (Nasdaq: NBP), a biotechnology platform company, announced new data from the expanded Phase 1 dosing study of ragistomig, a 4-1BB X PD-L1 bispecific antibody. The data will be presented at the ESMO-IO 2025 by ABL Bio. Poster (Abstract #688) to be presented by Gerald Falchook, MD, Director of Sarah Cannon Research Institute at HealthONE Denver, on December 10th at 5:30 PM GMT.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer